Rapid Dose Therapeutics Corp. announced a significant addition to the Company’s leadership team with the appointment of Rodney Butt as the lead consultant overseeing the development of the Company’s COVID-19 vaccine delivery platform. Initial results demonstrate viability and stability of both protein-based and mRNA-based vaccine candidates when incorporated into the oral dispersible film. Mr. Butt brings a wealth of expertise to RDT with more than 30 years prescription drug development experience. Rapid Dose Therapeutics would also like to confirm their commitment to bringing scientifically sound and medically relevant products to the market with the appointment Dr. Richard Tytus to the Company’s Advisory Board. Dr. Tytus will be responsible for supporting RDT’s leadership with strategic counsel and will facilitate introductions to relevant partners that will enhance commercialization of the RDT COVID-19 vaccine delivery system.